| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Investigative Ophthalmology & Visual Science, Vol 37, 2211-2218, Copyright © 1996 by Association for Research in Vision and Ophthalmology
ARTICLES AND REPORTS |
G Sartani, PB Silver, LV Rizzo, CC Chan, B Wiggert, G Mastorakos and RR Caspi
Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.
PURPOSE: Experimental autoimmune uveoretinitis (EAU) serves as a model for several immune-mediated diseases that affect the eye in humans. Previous studies indicated that tumor necrosis factor alpha (TNF-alpha) has an important proinflammatory role in EAU and possibly in human uveitis. In this study, the authors investigated the effect of anti-TNF- alpha therapy on EAU in mice. METHODS: Experimental autoimmune uveoretinitis was induced in B10.A mice by immunization with interphotoreceptor retinoid-binding protein (IRBP). The mice were treated with 100 or 300 microliters rabbit antiserum or polyclonal antibodies to human TNF-alpha. The treatment spanned either the afferent or the efferent stage of EAU (days -1, 1, 3, 5, 7, or days 8, 10, 12, 14, 16, respectively). Control animals were injected with preimmune rabbit serum at the corresponding times or were not treated. Three weeks after immunization, EAU was assessed by clinical evaluation and by histopathology. Immunologic responses were assessed by delayed- type hypersensitivity (DTH), lymphocyte proliferation to IRBP, and relative abundance of IRBP-primed splenocytes. RESULTS: The treatment with rabbit anti-TNF-alpha serum significantly ameliorated disease when given during the afferent stage but had no effect when given during the efferent stage of EAU. The effect on DTH, lymphocyte proliferation, and abundance of antigen-reactive cells roughly paralleled the effect on disease. CONCLUSIONS: Neutralization of systemic TNF ameliorates EAU. The effectiveness of afferent treatment in comparison to the treatment during the efferent stage, together with the reduced proliferation and the reduced abundance of IRBP-responsive cells, suggest that interference with afferent-acting processes such as antigen priming is important to achieve protection from EAU by anti-TNF treatment.
This article has been cited by other articles:
|
|
 |
|
  L. Lajavardi, A. Bochot, S. Camelo, B. Goldenberg, M.-C. Naud, F. Behar-Cohen, E. Fattal, and Y. de Kozak Downregulation of Endotoxin-Induced Uveitis by Intravitreal Injection of Vasoactive Intestinal Peptide Encapsulated in Liposomes Invest. Ophthalmol. Vis. Sci., July 1, 2007; 48(7): 3230 - 3238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sugita, H. Takase, C. Taguchi, and M. Mochizuki The Role of Soluble TNF Receptors for TNF-{alpha} in Uveitis Invest. Ophthalmol. Vis. Sci., July 1, 2007; 48(7): 3246 - 3252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Sobrin, E. C. Kim, W. Christen, T. Papadaki, E. Letko, and C. S. Foster Infliximab Therapy for the Treatment of Refractory Ocular Inflammatory Disease Arch Ophthalmol, July 1, 2007; 125(7): 895 - 900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Niccoli, C. Nannini, M. Benucci, D. Chindamo, E. Cassara, C. Salvarani, L. Cimino, G. Gini, I. Lenzetti, and F. Cantini Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study Rheumatology, July 1, 2007; 46(7): 1161 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Saurenmann, A. V. Levin, J. B. Rose, S. Parker, T. Rabinovitch, P. N. Tyrrell, B. M. Feldman, R. M. Laxer, R. Schneider, and E. D. Silverman Tumour necrosis factor {alpha} inhibitors in the treatment of childhood uveitis Rheumatology, August 1, 2006; 45(8): 982 - 989. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Hui-Yuen, T. T. Duong, and R. S. M. Yeung TNF-{alpha} Is Necessary for Induction of Coronary Artery Inflammation and Aneurysm Formation in an Animal Model of Kawasaki Disease J. Immunol., May 15, 2006; 176(10): 6294 - 6301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Toscano, A. G. Commodaro, J. M. Ilarregui, G. A. Bianco, A. Liberman, H. M. Serra, J. Hirabayashi, L. V. Rizzo, and G. A. Rabinovich Galectin-1 Suppresses Autoimmune Retinal Disease by Promoting Concomitant Th2- and T Regulatory-Mediated Anti-Inflammatory Responses J. Immunol., May 15, 2006; 176(10): 6323 - 6332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Murphy, K. Greiner, J. Plskova, L. Duncan, A. Frost, J. D. Isaacs, P. Rebello, H. Waldmann, G. Hale, J. V. Forrester, et al. Neutralizing Tumor Necrosis Factor Activity Leads to Remission in Patients With Refractory Noninfectious Posterior Uveitis Arch Ophthalmol, June 1, 2004; 122(6): 845 - 851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ali and E. Perlman Successful Treatment of Sarcoidosis Ann Intern Med, June 1, 2004; 140(11): W-48 - W-48. [Full Text]
|
|
|
|
|
|
K. Greiner, C. C. Murphy, F. Willermain, L. Duncan, J. Plskova, G. Hale, J. D. Isaacs, J. V. Forrester, and A. D. Dick Anti-TNF{alpha} Therapy Modulates the Phenotype of Peripheral Blood CD4+ T Cells in Patients with Posterior Segment Intraocular Inflammation Invest. Ophthalmol. Vis. Sci., January 1, 2004; 45(1): 170 - 176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Tezel and M. B. Wax Increased Production of Tumor Necrosis Factor-alpha by Glial Cells Exposed to Simulated Ischemia or Elevated Hydrostatic Pressure Induces Apoptosis in Cocultured Retinal Ganglion Cells J. Neurosci., December 1, 2000; 20(23): 8693 - 8700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D DICK and J. D ISAACS Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium Br. J. Ophthalmol., November 1, 1999; 83(11): 1230 - 1234. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
